CIK 0000811641
- Non-accelerated filer
- Smaller reporting company
IMMUCELL CORP /DE/
Sign in to watch- Ticker
- ICCC
- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 010382980
- Phone
- +1 207-878-2770
- Business address
- 56 EVERGREEN DR, PORTLAND, ME, 04103
- 4 Open-market buy Director bought 3,000 shares at an average $3.70 ($11,106)
- 4 Open-market buy Director bought 5,483 shares at an average $3.82 ($20,960)
- 4 Exercise or conversion Director acquired 2,000 shares (option exercise)
- 4 Open-market buy Director bought 2,777 shares at an average $5.91 ($16,417)
- 4 Open-market buy Director bought 1,696 shares at an average $5.56 ($9,430)
- 4 Open-market buy Director bought 4,450 shares at an average $5.75 ($25,590)
- 4 Open-market buy Director bought 2,357 shares at an average $5.39 ($12,701)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
- 4 Exercise or conversion Director acquired 15,000 shares (option exercise)
- 4 Open-market sale Director sold 12,500 shares at an average $6.75 ($84,392)
- 4 Open-market sale Director sold 2,500 shares at $6.90 ($17,241)
- 4 Exercise or conversion Vice President & CSO acquired 12,000 shares (option exercise)
- 4 Exercise or conversion President & CEO acquired 12,000 shares (option exercise)
- 4 Exercise or conversion President & CEO acquired 500 shares (option exercise)
- 4 Exercise or conversion Vice President & CSO acquired 500 shares (option exercise)
- 3 Insider Initial Statement of Ownership
- 4 Exercise or conversion Director acquired 15,000 shares (option exercise)
Page 11 of 13 · 256 filings